StreetInsider.com News Articles

Keros Therapeutics to receive $20M milestone from Takeda

Tue, 29 Sep 2026 08:02:35 -0400

Keros Therapeutics, Inc. (Nasdaq: KROS) announced it expects to receive a $20 million development milestone payment from Takeda following the dosing of the first patient in the ELRiSE MF clinical trial, a Phase 3 study evaluating elritercept against placebo in patients with myelofibrosis and anemia on concurrent ruxolitinib therapy.

The payment is triggered under the terms of a global license agreement with Takeda, which became effective in January 2025. Under that agreement, Keros received a $200 million upfront payment in February 2025 and is eligible for additional development, commercial, and sales milestones that could exceed $1.1 billion, along with tiered royalties

Form 8-K Keros Therapeutics, Inc. For: Sep 29

Tue, 29 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260929/27117804.html

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

Tue, 29 Sep 2026 08:00:00 -0400

LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

Tue, 29 Sep 2026 08:00:00 -0400

Form 8-K Keros Therapeutics, Inc. For: Sep 28

Mon, 28 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260928/27110350.html

Keros Therapeutics doses first patient in Phase 2 DMD rinvatercept trial

Mon, 28 Sep 2026 08:00:54 -0400

Keros Therapeutics, Inc. (Nasdaq: KROS) announced that the first patient has been dosed in its Phase 2 clinical trial evaluating rinvatercept in patients with Duchenne muscular dystrophy (DMD).

The trial, identified as NCT07704099, is an open-label, multi-cohort basket study. Its primary objective is to assess the safety and tolerability of rinvatercept in late-ambulatory and early non-ambulatory DMD patients. Secondary objectives include evaluating pharmacokinetics, anti-drug antibodies, body composition, and functional outcomes spanning skeletal muscle, motor, cardiac, and pulmonary measures.

Rinvatercept is a ligand trap designed to inhibit myostatin and activin A, which are described as negative regulators of muscle and bone mass. The

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Mon, 28 Sep 2026 08:00:00 -0400

LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”).

“Dosing the first patient in our Phase 2 clinical trial of rinvatercept represents an important step in advancing our neuromuscular development strategy, and reflects the

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Mon, 28 Sep 2026 08:00:00 -0400

“Dosing the first patient in our Phase 2 clinical trial of rinvatercept represents an important step in advancing our neuromuscular development strategy, and reflects the

Form EFFECT Keros Therapeutics, Inc.

Thu, 17 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260917/27072314.html

Form DEL AM Keros Therapeutics, Inc.

Fri, 11 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260911/27052811.html

Keros Therapeutics (KROS) files $350M mixed shelf

Thu, 10 Sep 2026 16:04:46 -0400

Keros Therapeutics (NASDAQ: KROS) filed $350,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants

Keros Therapeutics (KROS) files $350M mixed shelf

Thu, 10 Sep 2026 16:04:46 -0400

Keros Therapeutics (NASDAQ: KROS) filed $350,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants

Form S-3 Keros Therapeutics, Inc.

Thu, 10 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260910/27048302.html

Form 4 Keros Therapeutics, Inc. For: Aug 17 Filed by: BIENAIME JEAN JACQUES

Thu, 27 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991629.html

Form 4 Keros Therapeutics, Inc. For: Aug 17 Filed by: BIENAIME JEAN JACQUES

Thu, 27 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991629.html

Form 4 Keros Therapeutics, Inc. For: Aug 18 Filed by: Lerner Lorena Raquel